Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for iX Biopharma's PEG Ratio or its related term are showing as below:
SGX:42C's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.76 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
iX Biopharma PEG Ratio Related Terms
iX Biopharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for iX Biopharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where iX Biopharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
iX Biopharma (SGX:42C) has a PEG Ratio of 0.00 as of Aug. 06, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on iX Biopharma and its competitors. According to the industry distribution chart, iX Biopharma ranks #244 out of 350 companies in the Drug Manufacturers industry, placing it in the top 69.7%.
Is iX Biopharma's PEG Ratio too high?
iX Biopharma's current PEG Ratio is 0.00. Based on the distribution chart, iX Biopharma ranks #244 out of 350 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iX Biopharma ranks #244 out of 350 companies for PEG Ratio. This places iX Biopharma in the lower half of its industry. The industry median PEG Ratio is 1.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.76, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on iX Biopharma and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iX Biopharma's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1733.3% above its estimated fair value. The current PEG Ratio is 0.00. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current PEG Ratio is 0.00 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iX Biopharma (SGX:42C) Overvalued in 2026?
Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued.
The current stock price of S$0.55 is trading 1733.3% above its estimated GF Value™ of S$0.03.
GuruFocus considers iX Biopharma to be Significantly Overvalued.
Key valuation signals for SGX:42C:
PEG Ratio: 0.00
GF Value™: S$0.03 vs. price of S$0.55 (1733.3% above fair value)
No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score
Get the complete analysis for SGX:42C
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:42C has been successfully added to your 
